Molecular imaging

The second area of ​​research, which involves molecular imaging, uses technologies such as MRI and PET scans to assess the response to new therapies as quickly as possible. This research will use molecular tracers that infiltrate the tumor and allow us to see, early on, whether or not the tumor is responding to the therapies.

This aspect of research therefore works on different types of tumors both in patients, in the context of clinical trials, but also upstream in animals, on a dedicated preclinical imaging platform. This very upstream work will make it possible to evaluate the effectiveness of molecules very early on. The ultimate goal is to change patient care.

Treatment response assessment work in cancer concerns various pathologies: breast cancer, lymphoma, and prostate cancer.

Image-guided treatments include precision radiotherapy, interventional radiology and image-guided surgery. This is a major area of ​​development for the CGFL and the CHU.